Hosted on MSN1mon
Adial Pharmaceuticals secures new patent for addiction treatment
GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a ...
Business Insider24d
Adial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulation
Adial Pharmaceuticals (ADIL) announced a “positive” response from the U.S. FDA regarding its proposed in vitro bridging strategy for AD04. The FDA’s feedback follows Adial’s submission on ...
Hosted on MSN11mon
Adial stock rallies 81% on data for alcohol abuse drug
Adial said the article also included study results that showed low-dose AD04 did not significantly change certain liver injury biomarkers, including ALT, AST and serum bilirubin. GGT levels, which ...
Yahoo Finance17d
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...
Benzinga.com24d
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
The FDA agreed with Adial’s proposed 505(b)(2) bridging strategy, supporting AD04's progression to Phase 3 trials in 2025. Adial’s AD04-103 study shows bioavailability, dose proportionality ...
Yahoo Finance24d
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
GLEN ALLEN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical ...
WTNH1mon
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...
Nasdaq24d
Adial Pharmaceuticals Receives FDA's Positive Feedback On AD04 In Vitro Bridging Strategy
(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company, announced on Tuesday that it has received positive feedback from the U.S. Food and Drug Administration ...
Nasdaq1mon
Adial Reports Positive Results From AD04-103 Study
(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company, on Wednesday announced promising results from its AD04-103 Pharmacokinetics or PK Study for AD04 ...
Business Insider24d
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval ...
Investing1mon
Adial Pharmaceuticals secures new patent for addiction treatment
GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a new ...